INDIGENOUS BLOOM HEMP CORP (VRTHF)
| Symbol | VRTHF |
|---|
| Name | INDIGENOUS BLOOM HEMP CORP |
|---|
| Sector | UNDEFINED |
|---|
| Region | North America |
|---|
| Industry | - |
|---|
| Address | V6T 1Z3 Canada BC 101 - 2386 East Mal |
|---|
| Telephone | 778 968-6260 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | http://veritaspharmainc.com |
|---|
| Incorporation | CA |
|---|
| Incorporated On | 2014 |
|---|
| Employees | — |
|---|
| Fiscal Year | 4/30 |
|---|
| Public Since | — |
|---|
| Exchanges | OTC |
|---|
| Auditor | Saturna Group Chartered Professional Accountants LLP; |
|---|
| Audit Status | AUDITED |
|---|
| Reporting Status | International Reporting: Foreign Issuer - Not Listed on Foreign Exchange |
|---|
| CIK | — |
|---|
| Description | The medical marijuana industry is projected to have substantial growth over the next few years and Veritas is among the first to employ a comprehensive scientific approach behind medical marijuana claims. Our mission is to develop the most effective proprietary cannabis strains for specific disease conditions providing doctors and patients with conclusive scientific evidence for the recommendation and use of medical marijuana with confidence.
Veritas has formed an exclusive partnership and investment in Cannevert Therapeutics, a high-level research and development company, with its main office on the University of British Columbia (UBC) campus. Cannevert has brought together a highly accredited team of pharmacologists, anaesthetists and chemists with proven track records of success in drug development in both academia and industry. This alliance will provide Veritas with the required technical ability to achieve its goals in research, development and commercialization.
Additional info from OTC:
The medical marijuana industry is projected to have substantial growth over the next few years and Veritas is among the first to employ a comprehensive scientific approach behind medical marijuana claims. Our mission is to develop the most effective proprietary cannabis strains for specific disease conditions providing doctors and patients with conclusive scientific evidence for the recommendation and use of medical marijuana with confidence.
Veritas has formed an exclusive partnership and investment in Cannevert Therapeutics, a high-level research and development company, with its main office on the University of British Columbia (UBC) campus. Cannevert has brought together a highly accredited team of pharmacologists, anaesthetists and chemists with proven track records of success in drug development in both academia and industry. This alliance will provide Veritas with the required technical ability to achieve its goals in research, development and commercialization. |
|---|